Healthcare utilisation and costs in the diagnosis and treatment of progressive-fibrosing interstitial lung diseases. 2018

Colin Holtze, and Kevin Flaherty, and Michael Kreuter, and Fabrizio Luppi, and Teng Moua, and Carlo Vancheri, and Mary B Scholand
Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA choltze@med.umich.edu.

There are over 200 interstitial lung diseases (ILDs). In addition to patients with idiopathic pulmonary fibrosis (IPF), a percentage of patients with other ILDs also develop progressive fibrosis of the lung during their disease course. Patients with progressive-fibrosing ILDs may show limited response to immunomodulatory therapy, worsening symptoms and lung function and, ultimately, early mortality. There are few data for ILDs that may present a progressive fibrosing phenotype specifically, but we believe the burden and healthcare costs associated with these conditions may be comparable to those reported in IPF. This review discusses the burden of ILDs that may present a progressive fibrosing phenotype and the factors impacting healthcare utilisation.

UI MeSH Term Description Entries
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D011658 Pulmonary Fibrosis A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death. Alveolitis, Fibrosing,Idiopathic Diffuse Interstitial Pulmonary Fibrosis,Fibroses, Pulmonary,Fibrosis, Pulmonary,Pulmonary Fibroses,Alveolitides, Fibrosing,Fibrosing Alveolitides,Fibrosing Alveolitis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D015897 Comorbidity The presence of co-existing or additional diseases with reference to an initial diagnosis or with reference to the index condition that is the subject of study. Comorbidity may affect the ability of affected individuals to function and also their survival; it may be used as a prognostic indicator for length of hospital stay, cost factors, and outcome or survival.
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D017048 Health Care Costs The actual costs of providing services related to the delivery of health care, including the costs of procedures, therapies, and medications. It is differentiated from HEALTH EXPENDITURES, which refers to the amount of money paid for the services, and from fees, which refers to the amount charged, regardless of cost. Medical Care Costs,Treatment Costs,Costs, Medical Care,Health Costs,Healthcare Costs,Cost, Health,Cost, Health Care,Cost, Healthcare,Cost, Medical Care,Cost, Treatment,Costs, Health,Costs, Health Care,Costs, Healthcare,Costs, Treatment,Health Care Cost,Health Cost,Healthcare Cost,Medical Care Cost,Treatment Cost
D017563 Lung Diseases, Interstitial A diverse group of lung diseases that affect the lung parenchyma. They are characterized by an initial inflammation of PULMONARY ALVEOLI that extends to the interstitium and beyond leading to diffuse PULMONARY FIBROSIS. Interstitial lung diseases are classified by their etiology (known or unknown causes), and radiological-pathological features. Diffuse Parenchymal Lung Disease,Diffuse Parenchymal Lung Diseases,Interstitial Lung Disease,Interstitial Lung Diseases,Pneumonia, Interstitial,Pneumonitis, Interstitial,Interstitial Pneumonia,Interstitial Pneumonias,Interstitial Pneumonitides,Interstitial Pneumonitis,Lung Disease, Interstitial,Pneumonias, Interstitial,Pneumonitides, Interstitial
D018450 Disease Progression The worsening and general progression of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis. Clinical Course,Clinical Progression,Disease Exacerbation,Exacerbation, Disease,Progression, Clinical,Progression, Disease

Related Publications

Colin Holtze, and Kevin Flaherty, and Michael Kreuter, and Fabrizio Luppi, and Teng Moua, and Carlo Vancheri, and Mary B Scholand
September 2019, European respiratory review : an official journal of the European Respiratory Society,
Colin Holtze, and Kevin Flaherty, and Michael Kreuter, and Fabrizio Luppi, and Teng Moua, and Carlo Vancheri, and Mary B Scholand
November 2019, Current medical research and opinion,
Colin Holtze, and Kevin Flaherty, and Michael Kreuter, and Fabrizio Luppi, and Teng Moua, and Carlo Vancheri, and Mary B Scholand
February 2020, The New England journal of medicine,
Colin Holtze, and Kevin Flaherty, and Michael Kreuter, and Fabrizio Luppi, and Teng Moua, and Carlo Vancheri, and Mary B Scholand
February 2020, The New England journal of medicine,
Colin Holtze, and Kevin Flaherty, and Michael Kreuter, and Fabrizio Luppi, and Teng Moua, and Carlo Vancheri, and Mary B Scholand
February 2020, The New England journal of medicine,
Colin Holtze, and Kevin Flaherty, and Michael Kreuter, and Fabrizio Luppi, and Teng Moua, and Carlo Vancheri, and Mary B Scholand
May 2020, Zeitschrift fur Rheumatologie,
Colin Holtze, and Kevin Flaherty, and Michael Kreuter, and Fabrizio Luppi, and Teng Moua, and Carlo Vancheri, and Mary B Scholand
October 2019, The New England journal of medicine,
Colin Holtze, and Kevin Flaherty, and Michael Kreuter, and Fabrizio Luppi, and Teng Moua, and Carlo Vancheri, and Mary B Scholand
January 2022, Frontiers in medicine,
Colin Holtze, and Kevin Flaherty, and Michael Kreuter, and Fabrizio Luppi, and Teng Moua, and Carlo Vancheri, and Mary B Scholand
September 2019, The European respiratory journal,
Colin Holtze, and Kevin Flaherty, and Michael Kreuter, and Fabrizio Luppi, and Teng Moua, and Carlo Vancheri, and Mary B Scholand
February 2020, The New England journal of medicine,
Copied contents to your clipboard!